Polycystic Ovarian Syndrome - Pipeline Review, H2 2019

Published by Global Markets Direct on 18th November 2019 | Ref: 1464100 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Polycystic Ovarian Syndrome - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H2 2019, provides an overview of the Polycystic Ovarian Syndrome (Women's Health) pipeline landscape.

Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. The main risk factor for polycystic ovary syndrome (PCOS) is a family history. Other factors include type 2 diabetes and heart disease. Treatment includes hormone therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Ovarian Syndrome (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Polycystic Ovarian Syndrome (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome (Women's Health).

- The pipeline guide reviews pipeline therapeutics for Polycystic Ovarian Syndrome (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Polycystic Ovarian Syndrome (Women's Health) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Polycystic Ovarian Syndrome (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Ovarian Syndrome (Women's Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Polycystic Ovarian Syndrome (Women's Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome (Women's Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Polycystic Ovarian Syndrome - Overview

Polycystic Ovarian Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Polycystic Ovarian Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development

AbbVie Inc

Addex Therapeutics Ltd

Arkay Therapeutics LLC

BioRestorative Therapies Inc

Cadila Healthcare Ltd

EffRx Pharmaceuticals SA

KinDex Pharmaceuticals Inc

Polycystic Ovarian Syndrome - Drug Profiles

(celecoxib + metformin hydrochloride + valsartan) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elagolix sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KDT-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metformin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize PEDF for Women's Health - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

saroglitazar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ThermoStem - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polycystic Ovarian Syndrome - Dormant Projects

Polycystic Ovarian Syndrome - Discontinued Products

Polycystic Ovarian Syndrome - Product Development Milestones

Featured News & Press Releases

Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome

Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1464100 | GMDHC11451IDB

Number of Pages

50

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Markets Direct
30-04-2018

$2,000 USD

Published by Global Markets Direct
20-02-2018

$2,000 USD

Published by Global Markets Direct
17-10-2017

$2,000 USD

Published by Global Markets Direct
29-08-2017

$2,000 USD

Published by Global Markets Direct
09-05-2017

$2,000 USD

Published by Global Markets Direct
31-03-2017

$2,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Polycystic Ovarian Syndrome - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.